Allergenis develops a bead-based epitope assay (BBEA) that provides a highly accurate diagnostic test for peanut allergies, achieving 93% concordance with oral food challenges. This precision technology enables healthcare providers to deliver clear, data-driven answers regarding the risk of life-threatening allergic reactions.
Funding
$15.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic tests for peanut allergies often lack the accuracy needed to confidently determine the risk of life-threatening reactions, leading to uncertainty for both healthcare providers and patients. Existing methods may not provide a clear, quantitative assessment of a patient's sensitivity to specific peanut allergens. This limitation can result in unnecessary anxiety and overly cautious management strategies.
Solution
Allergenis offers a bead-based epitope assay (BBEA) that delivers a highly accurate and data-driven diagnostic test for peanut allergies. The assay analyzes multiple epitopes to create a unique allergy signature for each patient, providing a detailed quantification of their sensitivity. By identifying 'active' epitopes and their levels of reactivity, the platform enables greater stratification of treatment, including during immunotherapy. The test achieves 93% concordance with oral food challenges when clinically utilizing skin prick testing (SPT) and serum IgE (sIgE) as rule in/rule out criteria. This precision helps healthcare providers deliver clear answers regarding the risk of allergic reactions.
Target Audience
The primary audience includes healthcare providers, such as allergists and pediatricians, who require accurate and reliable diagnostic tools to assess peanut allergy risk in their patients.
Features
- Bead-based epitope assay (BBEA) for high-resolution peanut allergy diagnostics
- Multi-analyte laboratory developed test with algorithmic analyses
- Quantitative output derived from analyzing multiple peanut epitopes
- Identification of 'active' epitopes, reactivity levels, and treatment stage-specific responses
- 93% concordance with oral food challenges when clinically utilizing SPT and sIgE as rule in/rule out
- Provides a unique allergy signature for each patient